Mineralys Therapeutics (MLYS) News Today $14.34 +0.02 (+0.14%) Closing price 04:00 PM EasternExtended Trading$14.38 +0.04 (+0.24%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $155,453.10 in StockJuly 16 at 5:17 AM | insidertrades.comAdam Scott Levy Sells 10,758 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 15 at 7:44 PM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,366 SharesJuly 15 at 7:44 PM | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells 15,884 Shares of StockJuly 15 at 7:20 PM | marketbeat.comPromising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical SuccessJuly 14 at 4:07 PM | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 6.2% - Time to Sell?July 7, 2025 | marketbeat.comMineralys Therapeutics Announces Positive Phase 3 Launch-HTN Trial Results for Lorundrostat in Uncontrolled Hypertension - NasdaqJuly 2, 2025 | nasdaq.comHere's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn SituationJuly 2, 2025 | finance.yahoo.comMineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of LorundrostatJuly 1, 2025 | msn.comMineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for LorundrostatJune 30, 2025 | globenewswire.comMLYS - Mineralys Therapeutics Inc Key Metrics - MorningstarJune 26, 2025 | morningstar.comMResearch Analysts Issue Forecasts for MLYS Q2 EarningsJune 19, 2025 | marketbeat.comPromising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment AppealJune 18, 2025 | tipranks.comMineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock JumpsJune 17, 2025 | benzinga.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?June 17, 2025 | marketbeat.comMineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC WainwrightJune 17, 2025 | marketbeat.comPositive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy RatingJune 17, 2025 | tipranks.comMineralys Therapeutics stock jumps after positive kidney disease trial dataJune 17, 2025 | investing.comMineralys Therapeutics Shares Climb on Strong Results from Kidney Disease TrialJune 17, 2025 | msn.comMineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and AlbuminuriaJune 17, 2025 | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?June 16, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street ZenJune 14, 2025 | marketbeat.comJefferies initiates Mineralys Therapeutics stock with hold ratingJune 11, 2025 | uk.investing.comJefferies Initiates Coverage of Mineralys Therapeutics (MLYS) with Hold RecommendationJune 11, 2025 | msn.comWellington Management Group LLP Has $1.13 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)June 7, 2025 | marketbeat.comMineralys Therapeutics: Merits A Small 'Speculative' HoldingJune 3, 2025 | seekingalpha.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.9% - Should You Sell?May 31, 2025 | marketbeat.comPolar Asset Management Partners Inc. Raises Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 28, 2025 | marketbeat.comMineralys announces late-breaking presentation of data from Launch-HTN trialMay 27, 2025 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Position Lifted by Millennium Management LLCMay 26, 2025 | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)May 24, 2025 | globenewswire.comBalyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 21, 2025 | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular ProtectionMay 20, 2025 | globenewswire.comTema Etfs LLC Buys New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 20, 2025 | marketbeat.comPolar Asset Management Partners Inc. Has $1.22 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 19, 2025 | marketbeat.comSphera Funds Management LTD. Has $2.35 Million Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 18, 2025 | marketbeat.comMineralys at BofA Securities 2025: Lorundrostat’s Hypertension PromiseMay 16, 2025 | investing.comDavid Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMay 16, 2025 | insidertrades.comHC Wainwright Reaffirms "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)May 15, 2025 | marketbeat.comOrbimed Advisors LLC Sells 391,302 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 15, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.23 EPSMay 14, 2025 | marketbeat.comEarnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock risesMay 14, 2025 | uk.investing.comIntegral Health Asset Management LLC Buys 519,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 14, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comPositive Buy Rating for Lorundrostat Driven by Successful Trials and Future PotentialMay 13, 2025 | tipranks.comOptimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data ReleasesMay 13, 2025 | tipranks.comMineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 13, 2025 | finance.yahoo.comMineralys Therapeutics stock rises on better-than-expected Q1 resultsMay 12, 2025 | investing.comMineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call TranscriptMay 12, 2025 | seekingalpha.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.460.96▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼95▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACLX News Today MRUS News Today ZLAB News Today SRRK News Today ACAD News Today VKTX News Today SWTX News Today PTGX News Today MLTX News Today IMVT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
